Screener
Agios Pharmaceuticals AGIO Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $99,647 | $89,130 |
| Marketable securities | 517,929 | 765,295 |
| Accounts receivable, net | 20,112 | 10,577 |
| Inventory | 30,152 | 32,920 |
| Contract assets | 4,104 | — |
| Prepaid expenses and other current assets | 45,724 | 44,130 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's short-term investments?
- Agios Pharmaceuticals (AGIO) reported short-term investments of $517.93M in Q2 2026.
- How has Agios Pharmaceuticals's short-term investments changed year-over-year?
- Agios Pharmaceuticals's short-term investments decreased by 39.6% year-over-year, from $858.07M to $517.93M.
- What is the long-term trend for Agios Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's short-term investments has grown at a 11.4% compound annual growth rate (CAGR), from $445.49M to $765.3M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Agios Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude